Clinical Trials Browser

Phase EARLY_PHASE1 × lorlatinib × 90 days × Clear all

NCT06333899 2026-03-12

Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

Phase EARLY_PHASE1 Recruiting

Diffuse Intrinsic Pontine Glioma, Astrocytoma, Glioblastoma, Glioma